PI4KIIα is a novel regulator of tumor growth by its action on angiogenesis and HIF-1α regulation

Oncogene

Volumn 29, Issue 17, 2010, Pages 2550-2559

  Li, J ^a   Lu, Y ^a,b   Zhang, J ^a,b   Kang, H ^c   Qin, Z ^a,b   Chen, C ^a  

^a INSTITUTE OF BIOPHYSICS   (China)

^b INSTITUTE OF GEOLOGY AND GEOPHYSICS   (China)

^c CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

Phosphatidylinositol 4 kinase type IIa (PI4KIIa); tumor; angiogenesis; hypoxia inducible factor 1a (HIF 1 )

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL KINASE; PHOSPHATIDYLINOSITOL KINASE 2ALPHA; UNCLASSIFIED DRUG; HIF1A PROTEIN, HUMAN; PHOSPHATIDYLINOSITOL PHOSPHATE 4 KINASE; PHOSPHATIDYLINOSITOL PHOSPHATE 4-KINASE; PHOSPHOTRANSFERASE;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CONTROLLED STUDY; HELA CELL; HUMAN; HUMAN CELL; MALE; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR VASCULARIZATION; ANIMAL; BAGG ALBINO MOUSE; CELL MOTION; CELL PROLIFERATION; ENDOTHELIUM CELL; METABOLISM; NEOPLASM; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; PHYSIOLOGY;

MUS MUSCULUS;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANIMALS; CELL MOVEMENT; CELL PROLIFERATION; ENDOTHELIAL CELLS; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HELA CELLS; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MALE; MICE; MICE, INBRED BALB C; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PHOSPHOTRANSFERASES (ALCOHOL GROUP ACCEPTOR);

EID: 77951879261     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2010.14     Document Type: Article

References (41)

1. Craige B, Salazar G, Faundez V. (2008). Phosphatidylinositol-4-kinase type II alpha contains an AP-3-sorting motif and a kinase domain that are both required for endosome traffic. Mol Biol Cell 19: 1415-1426.
2. Di PG, De CP. (2006). Phosphoinositides in cell regulation and membrane dynamics. Nature 443: 651-657.
3. Drabkin D. (1949). The standardization of hemoglobin measurement. Am J Med Sci 217: 710-711.
4. Ferrara N. (2002). VEGF and the quest for tumour angiogenesis factors. Nat Rev Cancer 2: 795-803.
5. Folkman J. (1971). Tumor angiogenesis: therapeutic implications. N Engl J Med 285: 1182-1186.
6. Folkman J, Haudenschild C. (1980). Angiogenesis in vitro. Nature 288: 551-556.
7. Garcia-Cardena G, Folkman J. (1998). Is there a role for nitric oxide in tumor angiogenesis? J Natl Cancer Inst 90: 560-561.
8. Gehrmann T, Heilmeyer Jr LM. (1998). Phosphatidylinositol 4-kinases. Eur J Biochem 253: 357-370.
9. Gewinner C, Wang ZC, Richardson A, Teruya-Feldstein J, Etemad-moghadam D, Bowtell D et al. (2009). Evidence that inositol polyphosphate 4-phosphatase type II is a tumor suppressor that inhibits PI3K signaling. Cancer Cell 16: 115-125.
10. Grant DS, Kinsella JL, Fridman R, Auerbach R, Piasecki BA, Yamada Y et al. (1992). Interaction of endothelial cells with a laminin A chain peptide (SIKVAV) in vitro and induction of angiogenic behavior in vivo. J Cell Physiol 153: 614-625.
11. Guo J, Wenk MR, Pellegrini L, Onofri F, Benfenati F, De CP. (2003). Phosphatidylinositol 4-kinase type IIalpha is responsible for the phosphatidylinositol 4-kinase activity associated with synaptic vesicles. Proc Natl Acad Sci USA 100: 3995-4000.
12. Hanahan D, Folkman J. (1996). Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86: 353-364.
13. Heilmeyer Jr LM, Vereb Jr G, Vereb G, Kakuk A, Szivak I. (2003). Mammalian phosphatidylinositol 4-kinases. IUBMB Life 55: 59-65.
14. Hellwig-Burgel T, Rutkowski K, Metzen E, Fandrey J, Jelkmann W. (1999). Interleukin-1beta and tumor necrosis factor-alpha stimulate DNA binding of hypoxia-inducible factor-1. Blood 94: 1561-1567.
15. Hsuan JJ. (1993). Oncogene regulation by growth factors. Anticancer Res 13: 2521-2532.
16. Huang LE, Bunn HF. (2003). Hypoxia-inducible factor and its biomedical relevance. J Biol Chem 278: 19575-19578.
17. Jiang BH, Zheng JZ, Leung SW, Roe R, Semenza GL. (1997). Transactivation and inhibitory domains of hypoxia-inducible factor 1alpha. Modulation of transcriptional activity by oxygen tension. J Biol Chem 272: 19253-19260.
18. Kauffmann-Zeh A, Klinger R, Kauffmann-Zeh A, Endemann G, Waterfield MD, Wetzker R et al. (1994). Regulation of human type II phosphatidylinositol kinase activity by epidermal growth factor-dependent phosphorylation and receptor association. J Biol Chem 269: 31243-31251.
19. Koesters R, von Knebel DM. (2003). The Wnt signaling pathway in solid childhood tumors. Cancer Lett 198: 123-138.
20. Kubota Y, Kleinman HK, Martin GR, Lawley TJ. (1988). Role of laminin and basement membrane in the morphological differentiation of human endothelial cells into capillary-like structures. J Cell Biol 107: 1589-1598.
21. Kung AL, Wang S, Klco JM, Kaelin WG, Livingston DM. (2000). Suppression of tumor growth through disruption of hypoxia-inducible transcription. Nat Med 6: 1335-1340.
22. Lee JW, Bae SH, Jeong JW, Kim SH, Kim KW. (2004). Hypoxia-inducible factor (HIF-1)alpha: its protein stability and biological functions. Exp Mol Med 36: 1-12.
23. Melillo G, Musso T, Sica A, Taylor LS, Cox GW, Varesio L. (1995). A hypoxia-responsive element mediates a novel pathway of activation of the inducible nitric oxide synthase promoter. J Exp Med 182: 1683-1693.
24. Minogue S, Anderson JS, Waugh MG, dos Santos M, Corless S, Cramer R et al. (2001). Cloning of a human type ii phosphatidy-linositol 4-kinase reveals a novel lipid kinase family. J Biol Chem 276: 16635-16640.
25. Minogue S, Waugh MG, De Matteis MA, Stephens DJ, Berditchevski F, Hsuan JJ. (2006). Phosphatidylinositol 4-kinase is required for endosomal trafficking and degradation of the EGF receptor. J Cell Sci 119: 571-581.
26. Pan W, Choi SC, Wang H, Qin Y, Volpicelli-Daley L, Swan L et al. (2008). Wnt3a-mediated formation of phosphatidylinositol 4,5-bisphosphate regulates LRP6 phosphorylation. Science 321: 1350-1353.
27. Qin Y, Li L, Pan W, Wu D. (2009). Regulation of phosphatidylinositol kinases and metabolism by Wnt3a and Dvl2. J Biol Chem 284: 22544-22548.
28. Roskoski Jr R. (2004). The ErbB/HER receptor protein-tyrosine kinases and cancer. Biochem Biophys Res Commun 319: 1-11.
29. Salazar G, Zlatic S, Craige B, Peden AA, Pohl J, Faundez V. (2009). Hermansky-Pudlak syndrome protein complexes associate with phosphatidylinositol 4-kinase type II alpha in neuronal and non-neuronal cells. J Biol Chem 284: 1790-1802.
30. Scott GK, Dodson JM, Montgomery PA, Johnson RM, Sarup JC, Wong WL et al. (1991). p185HER2 signal transduction in breast cancer cells. J Biol Chem 266: 14300-14305.
31. Semenza GL. (2001). Hypoxia-inducible factor 1: oxygen homeostasis and disease pathophysiology. Trends Mol Med 7: 345-350.
32. Semenza GL. (2002). HIF-1 and tumor progression: pathophysiology and therapeutics. Trends Mol Med 8: S62-S67.
33. Simons JP, Al-Shawi R, Minogue S, Waugh MG, Wiedemann C, Evangelou S et al. (2009). Loss of phosphatidylinositol 4-kinase 2alpha activity causes late onset degeneration of spinal cord axons. Proc Natl Acad Sci USA 106: 11535-11539.
34. Tan C, Cruet-Hennequart S, Troussard A, Fazli L, Costello P, Sutton K et al. (2004). Regulation of tumor angiogenesis by integrin-linked kinase (ILK). Cancer Cell 5: 79-90.
35. Treins C, Giorgetti-Peraldi S, Murdaca J, Semenza GL, Van OE. (2002). Insulin stimulates hypoxia-inducible factor 1 through a phosphatidylinositol 3-kinase/target of rapamycin-dependent signaling pathway. J Biol Chem 277: 27975-27981.
36. Wang YJ, Wang J, Sun HQ, Martinez M, Sun YX, Macia E et al. (2003). Phosphatidylinositol 4 phosphate regulates targeting of clathrin adaptor AP-1 complexes to the Golgi. Cell 114: 299-310.
37. Waugh MG, Minogue S, Anderson JS, Balinger A, Blumenkrantz D, Calnan DP et al. (2003). Localization of a highly active pool of type II phosphatidylinositol 4-kinase in a p97/valosin-containing-protein-rich fraction of the endoplasmic reticulum. Biochem J 373: 57-63.
38. Weber G, Shen F, Prajda N, Yeh YA, Yang H, Herenyiova M et al. (1996). Increased signal transduction activity and down-regulation in human cancer cells. Anticancer Res 16: 3271-3282. (Pubitemid 127663748)
39. Xu Z, Huang G, Kandror KV. (2006). Phosphatidylinositol 4-kinase type IIalpha is targeted specifically to cellugyrin-positive glucose transporter 4 vesicles. Mol Endocrinol 20: 2890-2897.
40. Yamamoto S, Tomita Y, Hoshida Y, Iizuka N, Monden M, Yamamoto S et al. (2004). Expression level of valosin-containing protein (p97) is correlated with progression and prognosis of non-small-cell lung carcinoma. Ann Surg Oncol 11: 697-704. (Pubitemid 40486705)
41. Zhong H, Chiles K, Feldser D, Laughner E, Hanrahan C, Georgescu MM et al. (2000). Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics. Cancer Res 60: 1541-1545.